Novartis’ PD-(L)1 catch-up attempt stumbles in PhIII
Novartis’ 5-year-long quest to play catch-up in PD-(L)1 has failed in its first Phase III trial.
In a study on late-stage melanoma patients, adding their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
